These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 7756673

  • 1. Vitamin D analogs: new therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia.
    Yu J, Papavasiliou V, Rhim J, Goltzman D, Kremer R.
    Anticancer Drugs; 1995 Feb; 6(1):101-8. PubMed ID: 7756673
    [Abstract] [Full Text] [Related]

  • 2. Reversal of hypercalcemia with the vitamin D analogue EB1089 in a human model of squamous cancer.
    El Abdaimi K, Papavasiliou V, Rabbani SA, Rhim JS, Goltzman D, Kremer R.
    Cancer Res; 1999 Jul 15; 59(14):3325-8. PubMed ID: 10416587
    [Abstract] [Full Text] [Related]

  • 3. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
    Koike M, Koshizuka K, Kawabata H, Yang R, Taub HE, Said J, Uskokovic M, Tsuruoka N, Koeffler HP.
    Anticancer Res; 1999 Jul 15; 19(3A):1689-97. PubMed ID: 10470102
    [Abstract] [Full Text] [Related]

  • 4. Effects of 1,25(OH)2D3, EB1089, and analog V on PTHrP production, PTHrP mRNA expression and cell growth in SCC 2/88.
    Kunakornsawat S, Rosol TJ, Capen CC, Middleton RP, Hannah SS, Inpanbutr N.
    Anticancer Res; 2001 Jul 15; 21(5):3355-63. PubMed ID: 11848494
    [Abstract] [Full Text] [Related]

  • 5. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo.
    Haq M, Kremer R, Goltzman D, Rabbani SA.
    J Clin Invest; 1993 Jun 15; 91(6):2416-22. PubMed ID: 8514854
    [Abstract] [Full Text] [Related]

  • 6. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
    Kubota T, Koshizuka K, Koike M, Uskokovic M, Miyoshi I, Koeffler HP.
    Cancer Res; 1998 Aug 01; 58(15):3370-5. PubMed ID: 9699668
    [Abstract] [Full Text] [Related]

  • 7. Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089.
    Zhang X, Jiang F, Li P, Li C, Ma Q, Nicosia SV, Bai W.
    Clin Cancer Res; 2005 Jan 01; 11(1):323-8. PubMed ID: 15671562
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Regulation of parathyroid hormone-related protein production by a squamous carcinoma cell line in vitro.
    Merryman JI, Capen CC, McCauley LK, Werkmeister JR, Suter MM, Rosol TJ.
    Lab Invest; 1993 Sep 01; 69(3):347-54. PubMed ID: 8377475
    [Abstract] [Full Text] [Related]

  • 10. Regulation of gene Expression by 1alpha,25-dihydroxyvitamin D3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma Cells.
    Akutsu N, Lin R, Bastien Y, Bestawros A, Enepekides DJ, Black MJ, White JH.
    Mol Endocrinol; 2001 Jul 01; 15(7):1127-39. PubMed ID: 11435613
    [Abstract] [Full Text] [Related]

  • 11. Induction of parathyroid hormone-related peptide by the Ras oncogene: role of Ras farnesylation inhibitors as potential therapeutic agents for hypercalcemia of malignancy.
    Aklilu F, Park M, Goltzman D, Rabbani SA.
    Cancer Res; 1997 Oct 15; 57(20):4517-22. PubMed ID: 9377563
    [Abstract] [Full Text] [Related]

  • 12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov 15; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 13. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
    Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF.
    Clin Cancer Res; 2000 Mar 15; 6(3):901-8. PubMed ID: 10741714
    [Abstract] [Full Text] [Related]

  • 14. Ability of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo.
    Vegesna V, O'Kelly J, Said J, Uskokovic M, Binderup L, Koeffle HP.
    Anticancer Res; 2003 Mar 15; 23(1A):283-9. PubMed ID: 12680225
    [Abstract] [Full Text] [Related]

  • 15. Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3.
    Boehm MF, Fitzgerald P, Zou A, Elgort MG, Bischoff ED, Mere L, Mais DE, Bissonnette RP, Heyman RA, Nadzan AM, Reichman M, Allegretto EA.
    Chem Biol; 1999 May 15; 6(5):265-75. PubMed ID: 10322128
    [Abstract] [Full Text] [Related]

  • 16. Dysregulation of parathyroid hormone-like peptide expression and secretion in a keratinocyte model of tumor progression.
    Henderson J, Sebag M, Rhim J, Goltzman D, Kremer R.
    Cancer Res; 1991 Dec 15; 51(24):6521-8. PubMed ID: 1742725
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.
    Barreto AM, Schwartz GG, Woodruff R, Cramer SD.
    Cancer Epidemiol Biomarkers Prev; 2000 Mar 15; 9(3):265-70. PubMed ID: 10750664
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.